Core Viewpoint - The company, Pulaike (603566.SH), has received approval from the Ministry of Agriculture and Rural Affairs for its new veterinary drug, "Fluralaner Chewable Tablets," which is aimed at treating external parasites in dogs [1] Group 1: Product Approval - The new veterinary drug has been officially registered and is set to be effective as of January 7, 2026, following the issuance of the New Veterinary Drug Registration Certificate [1] - The approval was granted based on the regulations outlined in the Veterinary Drug Management Regulations and the Veterinary Drug Registration Measures [1] Group 2: Indications and Usage - The drug is indicated for the treatment of external parasites in dogs, specifically targeting ticks (Rhipicephalus sanguineus) and fleas (Ctenocephalides felis, Ctenocephalides canis) [1] - It can also be used as part of a treatment plan for flea allergy dermatitis [1]

普莱柯公告称，经农业农村部审查，批准公司及全资子公司洛阳惠中兽药有限公司等联合申报的"氟雷 拉纳咀嚼片"为新兽药，并公示核发《新兽药注册证书》。该兽药为二类，主要成分氟雷拉纳，用于治 疗犬体表蜱虫、跳蚤感染。其驱杀作用可持续12周，采用软咀嚼片制备工艺，适口性好。产品上市前还 应取得兽药产品批准文号，这对公司提升竞争力、推动宠物板块业绩增长有积极作用。 ...

格隆汇1月8日丨普莱柯(603566.SH)公布，根据《兽药管理条例》和《兽药注册办法》规定，经农业农 村部审查，批准公司及全资子公司洛阳惠中兽药有限公司等单位联合申报的"氟雷拉纳咀嚼片"为新兽 药，并于2026年1月7日公示了核发《新兽药注册证书》（中华人民共和国农业农村部公告第986号）事 项。 适应症：用于治疗犬体表的蜱虫（血红扇头蜱）、跳蚤（猫栉首蚤、犬栉首蚤）感染，可作为控制跳蚤 过敏性皮炎方案的一部分来应用。 ...

Core Viewpoint - The animal health sector experienced a significant increase of 3.8% on January 5, with Haili Biological leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 4023.42, up by 1.38% [1] - The Shenzhen Component Index closed at 13828.63, up by 2.24% [1] Group 2: Individual Stock Performance - Haili Biological (603718) closed at 6.58, with a rise of 7.87% and a trading volume of 461,200 shares, amounting to a transaction value of 302 million yuan [1] - Biological Shares (600201) closed at 16.06, increasing by 6.57% with a trading volume of 553,300 shares, totaling 88.5 million yuan [1] - ST Green Health (002868) closed at 35.40, up by 5.01% with a trading volume of 14,600 shares, amounting to 5.124 million yuan [1] - Shunlian Biological (688098) closed at 9.29, increasing by 4.62% with a trading volume of 65,000 shares, totaling 60.117 million yuan [1] - Ruipu Biological (300119) closed at 19.53, up by 4.05% with a trading volume of 78,500 shares, amounting to 151 million yuan [1] - KQ Biological (688526) closed at 15.68, increasing by 2.75% with a trading volume of 29,900 shares, totaling 46.631 million yuan [1] - Huisheng Biological (300871) closed at 21.25, up by 2.51% with a trading volume of 61,500 shares, amounting to 129 million yuan [1] - Qudongli (920275) closed at 8.91, increasing by 2.30% with a trading volume of 10,300 shares, totaling 911,930 yuan [1] - Placo (603566) closed at 12.71, up by 2.25% with a trading volume of 36,700 shares, amounting to 46.3405 million yuan [1] - Jinhai Biological (002688) closed at 6.03, increasing by 1.34% with a trading volume of 105,100 shares, totaling 63.2745 million yuan [1] Group 3: Capital Flow Analysis - The animal health sector saw a net inflow of 77.0149 million yuan from main funds, while retail funds experienced a net outflow of 33.0955 million yuan [1] - The main funds' net inflow for Haili Biological was -54.2922 million yuan, with a net outflow from retail funds of -35.0631 million yuan [2] - Ruipu Biological had a net inflow of 15.0755 million yuan from main funds, while retail funds saw a net inflow of 555.73 thousand yuan [2] - Biological Shares had a net inflow of 1.5843 million yuan from main funds, with a net outflow from retail funds of -1529.42 thousand yuan [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.05% on December 31, with Xianfeng Holdings leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.58 [1] Group 1: Market Performance - The closing price of Xianfeng Holdings was 3.73, down by 2.61%, with a trading volume of 182,700 shares and a transaction amount of 68.47 million [2] - The animal health sector's main stocks showed mixed performance, with *ST Lvkang rising by 2.46% to 33.71, while several others, including Xianfeng Holdings and Ruipu Bio, saw declines [1][2] - The total trading volume in the animal health sector was significant, with major stocks like Ruipu Bio and Xianfeng Holdings contributing to the overall market activity [2] Group 2: Capital Flow - The animal health sector saw a net outflow of 45.26 million from institutional investors, while retail investors contributed a net inflow of 39.94 million [2] - The capital flow data indicates that retail investors were more active in the market, with a notable net inflow compared to the outflow from institutional investors [2] - Specific stocks like Huisheng Bio and *ST Lvkang had varying levels of net inflow and outflow from different investor categories, reflecting diverse investor sentiment [3]

Investment Rating - Industry Rating: Recommended [4] Core Insights - The pork industry continues to face losses, with a focus on pig farming opportunities. The average price of live pigs is 11.59 CNY/kg, down 0.46% week-on-week. The total breeding sow inventory is 39.9 million heads, down 1.1% month-on-month and 2.1% year-on-year. The industry is experiencing ongoing losses, with self-bred and purchased pig farming losses at 130.11 CNY/head and 162.80 CNY/head respectively. The recent anti-dumping ruling may alleviate domestic pork supply pressure, leading to accelerated capacity reduction [2][12]. Summary by Sections Planting Industry Chain - The Ministry of Agriculture and Rural Affairs has initiated winter crop seed supervision checks to ensure seed safety for the upcoming spring and summer planting. The checks focus on key crops such as corn, rice, soybeans, cotton, and vegetables. The commercialization of genetically modified technology is expected to accelerate, enhancing self-sufficiency rates of key varieties. Recommended stocks include Beidahuang and Suqian Agricultural Development [1][11]. Pig Farming - The average price of live pigs is reported at 11.59 CNY/kg, with a slight decrease of 0.46% from the previous week. The average price for pig futures is 11,469 CNY/ton, reflecting a 1.07% increase. The average weight of pigs post-slaughter is 89.57 kg, with a month-on-month increase of 3.21% in slaughter volume [12][62][65]. Recommended Stocks - For pig farming, recommended stocks include: 1. Livestock sector: Lihua Stock, Muyuan Food, Shuanghui Development, Dekang Agriculture, Jingji Zhino, and Wens Foodstuff 2. Feed sector: Haida Group 3. Animal health sector: Jinhai Biological, Biological Shares, Placo, and Zhongmu Shares [2][12].

Investment Rating - The report maintains an investment rating of "Outperform" for the agriculture, forestry, animal husbandry, and fishery industry [1]. Core Insights - The livestock prices have stabilized after a decline, and the export volume of pet food has shown year-on-year growth [1]. - The industry is currently trading at a price-to-earnings (P/E) ratio and price-to-book (P/B) ratio below historical averages, indicating potential for valuation recovery [7]. Summary by Sections Market Review - In November 2025, the agriculture, forestry, animal husbandry, and fishery index increased by 1.15%, outperforming the CSI 300 index, which fell by 2.46%, resulting in a relative outperformance of 3.61 percentage points [7][10]. - The sub-industry performance showed that the forestry processing sector had the highest gains, while the pet food sector experienced declines [10]. Livestock Industry Data Tracking - **Swine Farming**: In November 2025, the average price of external three-yuan pigs was 11.59 yuan/kg, a month-on-month increase of 0.61%, but a year-on-year decrease of 30.13% [19]. - **Broiler Chickens**: The average price of white feather broiler chickens was 3.48 yuan/jin, with a month-on-month increase of 2.65% and a year-on-year decrease of 7.69% [26]. Pet Food - In November 2025, China's pet food export volume reached 33,400 tons, a year-on-year increase of 11.23%, while the export value was 11.8 million USD, a year-on-year decrease of 3.59% [34]. Investment Recommendations - The report suggests focusing on companies such as Muyuan Foods (牧原股份), Pulaike (普莱柯), and Guobao Pet (乖宝宠物), all rated as "Buy" [1].

Core Insights - The animal health sector experienced a slight increase of 0.42% on December 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 3890.45, up 0.36%, while the Shenzhen Component Index closed at 13140.22, up 0.66% [1] Stock Performance - Huisheng Biological (300871) closed at 20.75, with a rise of 2.47% and a trading volume of 45,200 shares, amounting to a transaction value of 92.96 million yuan [1] - Other notable performers included: - Qudongli (920275) at 9.27, up 2.43% [1] - Shenlian Biological (688098) at 9.01, up 2.15% [1] - Xianfeng Holdings (002141) at 3.74, up 1.91% [1] - Ruipu Biological (300119) at 19.60, up 1.87% [1] Capital Flow - The animal health sector saw a net outflow of 129 million yuan from institutional investors, while retail investors contributed a net inflow of 157 million yuan [2][3] - The detailed capital flow for selected stocks showed: - Xianfeng Holdings (002141) had a net inflow of 6.89 million yuan from institutional investors [3] - Ruipu Biological (300119) experienced a net outflow of 15.98 million yuan from institutional investors but a net inflow of 11.27 million yuan from retail investors [3] - Qudongli (920275) had a net inflow of 2.22 million yuan from retail investors [3]

本次股权转让交割手续完成后，公司仍持有中普生物48.99%的股权，中普生物将不再为公司控股子公 司，其财务数据不再纳入公司合并报表范围。 中牧实业股份有限公司关于放弃控股子公司 股权优先购买权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本次交易情况概述 中牧实业股份有限公司（以下简称"中牧股份"或"公司"）于2025年11月13日、2025年12月1日分别召开 公司第九届董事会2025年第十三次临时会议、2025年第三次临时股东会，审议通过《关于放弃控股子公 司股权优先购买权的议案》，同意公司放弃认购中信农业科技股份有限公司持有的中普生物制药有限公 司（以下简称"中普生物"）4.04%的股权，由普莱柯生物工程股份有限公司（以下简称"普莱柯"）或其 他第三方摘牌受让股权。具体内容详见公司于2025年11月15日披露的《中牧实业股份有限公司关于放弃 控股子公司股权优先购买权的公告》（公告编号：临2025-036）和2025年12月2日披露的《中牧实业股 份有限公司2025年第三次临时股东会决议公告》（公告编号： ...

Core Viewpoint - The company emphasizes its strategic focus on the pet sector, aiming for rapid business development through innovation and investment partnerships [1] Group 1: Strategic Focus - The company is committed to expanding its own brand product market by enhancing product innovation, optimizing channels, and improving service quality [1] - The company is exploring investment collaborations to diversify its pet product offerings, supporting the rapid growth of its pet business segment [1] Group 2: Vaccine Development - The company has no plans to diversify into human vaccines, despite the similarities in immune mechanisms between animal and human vaccines, due to significant differences in regulatory approval, application scenarios, and usage requirements [1]